2.1 Study Design
This study used a single-center cross-sectional design. We enrolled 49 pediatric patients with HM (Group 1) and 50 healthy volunteers (Group 2), who presented to Atatürk University Faculty of Dentistry Department of Pedodontics between 2018 and 2020 for oncological treatment. Children with acute myelocytic leukemia (AML), ALL, were included in the HM group. Children with malign melanoma, hodgkin lymphoma or non-hodgkin lymphoma, were excluded in the HM group because the number of children with these cancers was low. Healthy children presenting to the clinic for various reasons were included in the control group. The children in the control group did not have any systemic disease.